PR Newswire
Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers
📈
AI Sentiment
Highly Positive
9/10
- Home
- JNJ
as of 03-23-2026 1:25pm EST
$235.36
$0.03
-0.01%
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
| Founded: | 1886 | Country: | United States |
| Employees: | N/A | City: | NEW BRUNSWICK |
| Market Cap: | 589.2B | IPO Year: | 2003 |
| Target Price: | $233.42 | AVG Volume (30 days): | 6.3M |
| Analyst Decision: | Buy | Number of Analysts: | 19 |
| Dividend Yield: | Dividend Payout Frequency: | annual | |
| EPS: | 11.03 | EPS Growth: | 90.50 |
| 52 Week Low/High: | $141.50 - $251.71 | Next Earning Date: | 04-14-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 6.63% | Revenue Growth (next year): | 7.19% |
| P/E Ratio: | 21.34 | Index: | |
| Free Cash Flow: | 19.7B | FCF Growth: | -5.53% |
AI-Powered JNJ Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 18 hours ago
AI Recommendation
hold
Model Accuracy: 70.35%
70.35%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Johnson & Johnson (JNJ)
Decker Robert J
Sell
VP Corporate Controller
JNJ Feb 27, 2026
Avg Cost/Share
$247.87
Shares
4,075
Total Value
$1,010,070.25
Owned After
23,682
SEC Form 4
Schmid Timothy
Sell
EVP, WW Chair, MedTech
JNJ Feb 20, 2026
Avg Cost/Share
$245.66
Shares
1,322
Total Value
$324,762.52
Owned After
25,447
SEC Form 4
Schmid Timothy
Sell
EVP, WW Chair, MedTech
JNJ Feb 18, 2026
Avg Cost/Share
$244.37
Shares
22,623
Total Value
$5,527,505.94
Owned After
25,447
Broadhurst Vanessa
Sell
EVP, Global Corp Affairs
JNJ Feb 17, 2026
Avg Cost/Share
$243.39
Shares
12,394
Total Value
$3,016,575.66
Owned After
23,003
REED JOHN C
Sell
EVP, Innovative Medicine, R&D
JNJ Feb 17, 2026
Avg Cost/Share
$243.00
Shares
53,931
Total Value
$13,105,233.00
Owned After
10,658
Wolk Joseph J
Sell
Exec VP, CFO
JNJ Feb 17, 2026
Avg Cost/Share
$242.82
Shares
89,654
Total Value
$21,767,826.99
Owned After
14,000
Swanson James D.
Sell
EVP, CIO
JNJ Feb 17, 2026
Avg Cost/Share
$242.70
Shares
20,521
Total Value
$4,980,446.70
Owned After
25,698.131
SEC Form 4
Swanson James D.
Sell
EVP, CIO
JNJ Feb 13, 2026
Avg Cost/Share
$243.74
Shares
41,559
Total Value
$10,129,312.29
Owned After
25,698.131
Duato Joaquin
Sell
CEO and Chairman of the Board
JNJ Jan 26, 2026
Avg Cost/Share
$221.24
Shares
100,000
Total Value
$22,122,893.44
Owned After
30,852
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Decker Robert J | JNJ | VP Corporate Controller | Feb 27, 2026 | Sell | $247.87 | 4,075 | $1,010,070.25 | 23,682 | |
| Schmid Timothy | JNJ | EVP, WW Chair, MedTech | Feb 20, 2026 | Sell | $245.66 | 1,322 | $324,762.52 | 25,447 | |
| Schmid Timothy | JNJ | EVP, WW Chair, MedTech | Feb 18, 2026 | Sell | $244.37 | 22,623 | $5,527,505.94 | 25,447 | |
| Broadhurst Vanessa | JNJ | EVP, Global Corp Affairs | Feb 17, 2026 | Sell | $243.39 | 12,394 | $3,016,575.66 | 23,003 | |
| REED JOHN C | JNJ | EVP, Innovative Medicine, R&D | Feb 17, 2026 | Sell | $243.00 | 53,931 | $13,105,233.00 | 10,658 | |
| Wolk Joseph J | JNJ | Exec VP, CFO | Feb 17, 2026 | Sell | $242.82 | 89,654 | $21,767,826.99 | 14,000 | |
| Swanson James D. | JNJ | EVP, CIO | Feb 17, 2026 | Sell | $242.70 | 20,521 | $4,980,446.70 | 25,698.131 | |
| Swanson James D. | JNJ | EVP, CIO | Feb 13, 2026 | Sell | $243.74 | 41,559 | $10,129,312.29 | 25,698.131 | |
| Duato Joaquin | JNJ | CEO and Chairman of the Board | Jan 26, 2026 | Sell | $221.24 | 100,000 | $22,122,893.44 | 30,852 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Jan 21, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYJan 21, 2026 · 100% conf.
AI Prediction BUY
1D
-0.12%
$217.75
Act: +0.22%
5D
+2.30%
$223.03
Act: +4.48%
20D
+2.19%
$222.78
Act: +13.25%
Price: $218.01 Prob +5D: 100% AUC: 1.000
0000200406-26-000002
jnj-202601210000200406false00002004062026-01-212026-01-210000200406us-gaap:CommonStockMember2026-01-212026-01-210000200406jnj:A1.150NotesDueNovember2028Member2026-01-212026-01-210000200406jnj:A2.700NotesDueFebruary2029Member2026-01-212026-01-210000200406jnj:A3.20NotesDueJune2032Member2026-01-212026-01-210000200406jnj:A3.050NotesDueFebruary2033Member2026-01-212026-01-210000200406jnj:A1.650NotesDueMay2035Member2026-01-212026-01-210000200406jnj:A3.350NotesDueJune2036Member2026-01-212026-01-210000200406jnj:A3.350NotesDueFebruary2037Member2026-01-212026-01-210000200406jnj:A3.550NotesDueJune2044Member2026-01-212026-01-210000200406jnj:A3.600NotesDueFebruary2045Member2026-01-212026-01-210000200406jnj:A3.700NotesDueFebruary2055Member2026-01-212026-01-21
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 21, 2026 Johnson & Johnson (Exact name of registrant as specified in its charter)
New Jersey1-321522-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number)(IRS Employer Identification No.)
One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: 732-524-0400 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, Par Value $1.00JNJNew York Stock Exchange 1.150% Notes Due November 2028JNJ28New York Stock Exchange 2.700% Notes due February 2029JNJ29BNew York Stock Exchange 3.200% Notes Due June 2032JNJ32New York Stock Exchange 3.050% Notes due February 2033JNJ33BNew York Stock Exchange 1.650% Notes Due May 2035JNJ35New York Stock Exchange 3.350% Notes Due June 2036JNJ36ANew York Stock Exchange 3.350% Notes due February 2037JNJ37BNew York Stock Exchange 3.550% Notes Due June 2044JNJ44New York Stock Exchange 3.600% Notes due February 2045JNJ45New York Stock Exchange 3.700% Notes due February 2055JNJ55New York Stock Exchange
Item 2.02 Results of operations and financial condition On January 21, 2026, Johnson & Johnson (the “Company”) issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the fourth quarter and full year ended December 28, 2025.
Item 9.01 Financial statements and exhibits (d) Exhibits.
Exhibit No.Description of Exhibit 99.1 Press Release dated January 21, 2026 for the period ended December 28, 2025
99.2 Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the fiscal fourth quarter and full year
104The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 21, 2026
JOHNSON & JOHNSON
(Registrant)
By:/s/ Robert J. Decker, Jr.
Robert J. Decker, Jr. Controller (Principal Accounting Officer)
2025 Q3 Q3 2025 Earnings
8-K Oct 14, 2025
2025
Q3
Q3 2025 Earnings
8-KOct 14, 2025
0000200406-25-000201
jnj-202510140000200406false00002004062025-10-142025-10-140000200406us-gaap:CommonStockMember2025-10-142025-10-140000200406jnj:A1.150NotesDueNovember2028Member2025-10-142025-10-140000200406jnj:A2.700NotesDueFebruary2029Member2025-10-142025-10-140000200406jnj:A3.20NotesDueNovember2032Member2025-10-142025-10-140000200406jnj:A3.050NotesDueFebruary2033Member2025-10-142025-10-140000200406jnj:A1.650NotesDue2035Member2025-10-142025-10-140000200406jnj:A3.350NotesDueNovember2036Member2025-10-142025-10-140000200406jnj:A3.350NotesDueFebruary2037Member2025-10-142025-10-140000200406jnj:A3.550NotesDueNovember2044Member2025-10-142025-10-140000200406jnj:A3.600NotesDueFebruary2045Member2025-10-142025-10-140000200406jnj:A3.700NotesDueFebruary2055Member2025-10-142025-10-14
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 14, 2025 Johnson & Johnson (Exact name of registrant as specified in its charter)
New Jersey1-321522-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number)(IRS Employer Identification No.)
One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: 732-524-0400 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, Par Value $1.00JNJNew York Stock Exchange 1.150% Notes Due November 2028JNJ28New York Stock Exchange 2.700% Notes due February 2029JNJ29BNew York Stock Exchange 3.200% Notes Due June 2032JNJ32New York Stock Exchange 3.050% Notes due February 2033JNJ33BNew York Stock Exchange 1.650% Notes Due May 2035JNJ35New York Stock Exchange 3.350% Notes Due June 2036JNJ36ANew York Stock Exchange 3.350% Notes due February 2037JNJ37BNew York Stock Exchange 3.550% Notes Due June 2044JNJ44New York Stock Exchange 3.600% Notes due February 2045JNJ45New York Stock Exchange 3.700% Notes due February 2055JNJ55New York Stock Exchange
Item 2.02 Results of operations and financial condition On October 14, 2025, Johnson & Johnson (the “Company”) issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the third quarter ended September 28, 2025.
Item 8.01 Other events On October 14, 2025, the Company issued the attached press release (Exhibit 99.3) announcing its intent to separate the Company's Orthopaedics business.
Item 9.01 Financial statements and exhibits (d) Exhibits.
Exhibit No.Description of Exhibit 99.1 Press Release dated October 14, 2025 for the period ended September 28, 2025
99.2 Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the fiscal third quarter and nine months
99.3 Press Release dated October 14, 2025
104The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 14, 2025
JOHNSON & JOHNSON
(Registrant)
By:/s/ Robert J. Decker, Jr.
Robert J. Decker, Jr. Controller (Principal Accounting Officer)
2025 Q2 Q2 2025 Earnings
8-K Jul 16, 2025
2025
Q2
Q2 2025 Earnings
8-KJul 16, 2025
0000200406-25-000170
jnj-202507160000200406false00002004062025-07-162025-07-160000200406us-gaap:CommonStockMember2025-07-162025-07-160000200406jnj:A1.150NotesDueNovember2028Member2025-07-162025-07-160000200406jnj:A2.700NotesDueFebruary2029Member2025-07-162025-07-160000200406jnj:A3.20NotesDueNovember2032Member2025-07-162025-07-160000200406jnj:A3.050NotesDueFebruary2033Member2025-07-162025-07-160000200406jnj:A1.650NotesDue2035Member2025-07-162025-07-160000200406jnj:A3.350NotesDueNovember2036Member2025-07-162025-07-160000200406jnj:A3.350NotesDueFebruary2037Member2025-07-162025-07-160000200406jnj:A3.550NotesDueNovember2044Member2025-07-162025-07-160000200406jnj:A3.600NotesDueFebruary2045Member2025-07-162025-07-160000200406jnj:A3.700NotesDueFebruary2055Member2025-07-162025-07-16
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 16, 2025 Johnson & Johnson (Exact name of registrant as specified in its charter)
New Jersey1-321522-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number)(IRS Employer Identification No.)
One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: 732-524-0400 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, Par Value $1.00JNJNew York Stock Exchange 1.150% Notes Due November 2028JNJ28New York Stock Exchange 2.700% Notes due February 2029JNJ29BNew York Stock Exchange 3.200% Notes Due June 2032JNJ32New York Stock Exchange 3.050% Notes due February 2033JNJ33BNew York Stock Exchange 1.650% Notes Due May 2035JNJ35New York Stock Exchange 3.350% Notes Due June 2036JNJ36ANew York Stock Exchange 3.350% Notes due February 2037JNJ37BNew York Stock Exchange 3.550% Notes Due June 2044JNJ44New York Stock Exchange 3.600% Notes due February 2045JNJ45New York Stock Exchange 3.700% Notes due February 2055JNJ55New York Stock Exchange
Item 2.02 Results of operations and financial condition On July 16, 2025, Johnson & Johnson issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the second quarter ended June 29, 2025.
Item 9.01 Financial statements and exhibits (d) Exhibits.
Exhibit No.Description of Exhibit 99.1 Press Release dated July 16, 2025 for the period ended June 29, 2025
99.2 Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the fiscal second quarter and six months
104The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date:July 16, 2025
JOHNSON & JOHNSON
(Registrant)
By:/s/ Robert J. Decker, Jr.
Robert J. Decker, Jr. Controller (Principal Accounting Officer)
Latest Johnson & Johnson News
JNJ Breaking Stock News: Dive into JNJ Ticker-Specific Updates for Smart Investing
MarketBeat
Protagonist Therapeutics Soars as FDA Approves ICOTYDE for Plaque Psoriasis, Triggers $50M Milestone
📈
AI Sentiment
Highly Positive
10/10
Insider Monkey
Jim Cramer on Johnson & Johnson: “It’s a Textbook Slowdown Stock”
📊
AI Sentiment
Positive
7/10
Simply Wall St.
Monte Rosa J J Supply Deal Refocuses MRT 2359 Prostate Cancer Story
📊
AI Sentiment
Positive
7/10
Zacks
Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here's Why
📈
AI Sentiment
Highly Positive
9/10
Zacks
Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?
📈
AI Sentiment
Highly Positive
8/10
Financial Planning
After notable victories, anti-DEI shareholders turn sights on Trump's SEC
➖
AI Sentiment
Neutral
4/10
Packaging Gateway
Origin Materials and HP Embalagens enter PET cap distribution deal
📈
AI Sentiment
Highly Positive
8/10
Compare JNJ vs Leading Stocks
See how JNJ stacks up against similar companies in the market
Head-to-Head Comparisons
More Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "JNJ Johnson & Johnson - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.